Member Info for RayPointer

I was thinking along the same lines Johnny.

We will probably never know what the current situation is.

The other point I would make about SC129 is that Scancell intend to trial it as a bi-specific antibody once funds permit.

That does leave other options available to pharmas e.g. Car-T or attaching an ADC as two examples.

I think we are in the middle of a Suzy Q and A session

He has a successful lab to run 😂

I seem to remember that Lindy mentioned BMS in connection with Glycans, but I think she also said that their work did not show the same promise as Scancell's work (or words to that effect).

That was at one of the recent AGMs.

Of course it matters

1) TRX

2) Ambrose

3) Sanderson

Spot the pattern

Sorry first link should be:

https://find-and-update.company-information.service.gov.uk/company/08203248

Click on "people"

Https://find-and-update.company-information.service.gov.uk/company/08203248

Yes, I see what you mean.

"This company investing used to be called Beaufort Securities. They were as bent as a two bob note. Something dodgy if you ask me!"

I think the connection is that the boss of Sanderson was also the boss of Beaufort Securities.

Beaufort Securities crashed in spectacular fashion

https://www.ft.com/content/24db2600-22ff-11e8-add1-0e8958b189ea

It's good to see Scancell scientists other than Lindy taking part in conferences.

Let's hope it's a sign that Lindy is too busy talking to parties who are interested in doing deals 😀

A lot of credit due Lindy's success with Glycans mAbs.

PM is leader of the "Deal by the end of March" party.

We await the reasoning behind this deadline.

"crowdfunding" page coming soon 😂

Dalester, let's hope that there is more than just one Godot on the way 😂

The question is how much is a product worth if :

a) any clinical or pre-clinical results have not been peer reviewed?

b) pharma have shown no interest in the product so far?

c) the product has not been showcased at conferences?

d) there has been little or nothing published in scientific journals about the product?

I'm not sure that the latest Iceman incarnation is a blithering idiot.

He may be a clever pumper and dumper just sounding out sentiment 😂

Maybe the £ was a typo as well 🤣

"Keep taking the pills Mikie! Is that 600 tons cathode, pure Cu, oxide, sulphate or coppers helmets? !"

Obviously kitchen units!

https://homedesignboard.com/todays-design/a-touch-of-copper/

Hi TF

Yes, you're right, the tumour must be unresectable.

Hi Cleaner

This thread is about the 5 companies interested in glymabs as stated by Lindy in the investors' presentation.

I was just speculating whether or not BionTech is one of those companies.

Switching to melanoma, the Moderna trial is for an MRNA vaccine with CPI targeting resected melanoma and it is personalised to the mutations exhibited by each patient.

This is a different market to the Scope trial which is targeting unresected melanoma. As such, it is not in the same race.

"Agree however, somebody mentioned that once the data starts to come in Biontech would not be able to afford it?"

This was Lindy speaking in jest, and she was talking about Modi1.

But yes, there is no reason why BionTech should not be interested in any or all of Scancell's four platforms.

ATB

I think that this has been posted previously, but it could be worth a discussion.

https://www.biospace.com/article/biontech-forges-first-deal-of-the-year-building-on-2024-cancer-focus-/

Lindy's mate Ugur Sahin has been busy doing antibody deals including a bi-specific antibody.

I just wonder if BionTech are one of the 5 interested companies.